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Background and objectives: The aim of this study was to test the effects of individual schema therapy (ST)
for patients with chronic depression.
Methods: Using a multiple-baseline single case series design, patients with chronic major depressive
disorder (N ¼ 25) first entered a 6e24 weeks baseline phase; this phase functioned as a no-treatment
control condition. Then, patients started a 12 week exploration phase during which symptoms and
underlying schemas were explored; this phase functioned as an attention control condition. Next, pa-
tients received up to 65 sessions of individual ST. The Beck Depression Inventory II (BDI-II) and the Quick
Inventory of Depressive Symptomatology (QIDS) were the primary outcome measures. The BDI-II was
assessed once a week during all phases of the study resulting in 100 repeated assessments per partic-
ipant on average. Mixed regression analysis was used to contrast change in symptoms during the
intervention with change in symptoms during the baseline and exploration control phases.
Results: When compared to the no-treatment control period, the intervention had a significant, large
effect on depressive symptoms (Cohen's d BDI-II ¼ 1.30; Cohen's d QIDS ¼ 1.22). Effects on secondary
continuous outcomes were moderate to large.
Limitations: The small sample size and lack of a control group.
Conclusions: These findings provide evidence that ST might be an effective treatment for patients with
chronic depression.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
About one in five patients with depression develops a chronic
course defined as the presence of depressive symptoms for two
years or longer (Keller, Hanks, Kocsis, & Klein, 1995). Pharmaco-
logical and psychotherapeutic interventions for chronic depression
are effective but meta analyses have shown that the effect sizes of
psychotherapy are generally low (d¼ 0.23; Cuijpers et al., 2010) andiences Unit, 15 Chaucer Road,
F. Renner).
aastricht University, P.O. Boxremission rates following treatment with antidepressant medica-
tion are usually below 50% (for a review see: Kocsis, 2003), high-
lighting the need for treatment innovation for chronic depression.
One promising psychotherapeutic intervention in this respect is the
cognitive behavioral analysis system of psychotherapy (CBASP)
(McCullough, 2003). Randomized controlled trials (RCTs) have
shown that CBASP is at least as effective as antidepressant medi-
cation (Keller et al., 2000) and regular care (Wiersma et al., 2014)
and more effective than regular care at 52 weeks follow-up
(Wiersma et al., 2014). Although these findings are promising,
about two-thirds of the patients who received CBASP in these
studies did not remit, illustrating that there is room for improve-
ment and a need to explore novel treatments for chronic
depression.
Table 1
Overview of the demographic and clinical characteristics of the sample.






















BDI-II score at screening 32.96 (9.37)
# Previous episodes 2.80 (2.14)
Secondary current axis-I diagnosis
None 14 (56%)
Anxiety disorder 6 (24%)
Other 5 (20%)
Secondary current axis-II diagnosis
None 9 (32%)
Depressive PD 9 (36%)
Avoidant PD 7 (28%)
Obsessive compulsive PD 6 (24%)
Dependent PD 1 (4%)
Antidepressant use at baseline 11 (44%)
Note. BDI-II ¼ Beck Depression Inventory e second edition.
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e73 67Chronic depression is often rooted in traumatic childhood ex-
periences (Wiersma et al., 2009) and personality pathology (Fava
et al., 1996; Hayden & Klein, 2001; Holmstrand, Engstr€om, &
Tr€askman-Bendz, 2008; Pepper et al., 1995). Current short-term,
symptom focused treatments might fall short in addressing these
factors sufficiently. We have argued that schema therapy (ST), a
psychological treatment with a strong emphasis on childhood ex-
periences and personality pathology, could be an effective treat-
ment for chronic depression (Renner, Arntz, Leeuw, & Huibers,
2013). ST has established effectiveness in treating borderline
(Giesen-Bloo et al., 2006; Nadort et al., 2009; Nordahl & Nysaeter,
2005) and primarily Cluster-C personality disorders (Bamelis,
Evers, Spinhoven, & Arntz, 2013) and initial evidence suggests
that ST could also be an effective treatment for chronic depression:
Brewin et al. (2009) reported positive and large effects of imagery
rescripting, a key-technique in ST, on depressive symptoms in pa-
tients with chronic depression. Carter et al. (2013) found compa-
rable remission rates between a short ST protocol and cognitive
therapy (CT) in a RCT (remission rates in ST: 50%; remission rates in
CT: 40%). Malogiannis et al. (2014) tested a longer ST protocol in
chronically depressed women in a case series and found large ef-
fects on depressive symptoms and approximately 60% of patients
remitted.
Although these initial findings are promising, there is a need to
further test the effects of ST for chronic depression with an
appropriate amount of sessions. The current study advances pre-
vious studies by testing the effects of up to 65 individual sessions of
ST in 25 patients with chronic depression using a multiple-baseline
single case series design. Single case series are important research
designs in the development of new treatments. They are recognized
alternatives to cohort and case-control studies and have the
advantage of smaller sample sizes compared to RCTs. The strength
of the multiple-baseline design used in the current study above a
single case series without multiple baselines (Malogiannis et al.,
2014) is that, comparable to a RCT, symptomatic improvements
during treatment can be attributed to the intervention rather than
the mere passage of time (Kazdin, 1982). An extra asset of the
current study is that, in addition to a random baseline period, we
included an exploration phase during which therapists were
instructed to not use any interventions aimed at changing symp-
toms. We hypothesized that ST would lead to a decrease in
depressive symptom severity when compared to symptom change
during the non-treatment control (baseline) phase or the explora-
tion phase.2. Methods
2.1. Participants
Twenty-five patients with chronic depression were recruited
from a specialized secondary mental health facility in the
Netherlands (RIAGG Maastricht). Table 1 shows demographic and
clinical characteristics of the sample. Study procedures were pre-
specified prior to recruitment (clinicaltrials.gov: NCT01153867).
Inclusion criteria were: (a) DSM-IV diagnosis of major depressive
disorder for  2 years as indicated by the Structured Clinical
Interview for DSM-IV Axis-I Disorders (SCID-I; First, Spitzer,
Gibbon, & Williams, 1997); (b) scoring  20 on the Beck2 Since schema therapy is a quite intense intervention we wanted to make sure
that participants have a sufficiently high level of depressive symptom severity (i.e.
at least moderate levels of depression). This was confirmed by a BDI-II score 20 at
the screening appointment, indicating at least moderate levels of depression (Beck
et al. 1996).Depression Inventory second edition (BDI-II; Beck, Steer, & Brown,
1996)2; (c) age between 18 and 65 years. Exclusion criteria were: a
DSM-IV current or past diagnosis of major depression with psy-
chotic features; current or past bipolar disorder; current or past
psychotic disorder; alcohol or drug dependence or a autism spec-
trum disorder, as assessed with the SCID-I. Patients with cluster-A
or cluster-B personality disorders, as assessed with the SCID-II,
were also excluded. Patients with cluster-A and cluster-B person-
ality disorders were excluded because these personality disorders
were viewed as so complex that they would need specialized
treatment. Patients with cluster-C personality disorders where not
excluded due to the high co-morbidity with chronic depression.
Additional exclusion criteria were acute suicide risk and inability to
speak and read the Dutch language. Patients taking antidepressant
medication were excluded, unless they were stable on medication
for at least three months prior to screening.3 The study was
approved by the medical ethical committee of the University
Hospital Maastricht, the Netherlands. Informed consent was ob-
tained after study procedures were explained to participants and all
procedures were in line with the Declaration of Helsinki.2.2. Design
A non-concurrent multiple random baseline design (Kazdin,
1982) consisting of three phases was used: 1) A baseline phase
consisting of a 6e24 weeks waiting period that served as a no-3 Medication dosage of one participant taking venlafaxine was increased from
75 mg to 150 mg two month prior to start of the study.
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e7368treatment control phase. The duration of the baseline phase was
quasi-random (dependent on the waiting time at the clinic). 2) An
exploration phase lasting 12 weeks with 8e10 exploration-sessions
that served as an additional control phase. 3) An intervention
phase, consisting of up to 65 individual sessions ST as described
below. Therapists were instructed to not exceed a total of 75 ses-
sions (exploration þ intervention phase). During all study phases
depressive symptom severity and additional outcomes (described
in assessments) were repeatedly assessed.
2.3. Assessments
Self-report assessments were completed via a web-based sys-
tem throughout the three study phases and included weekly
measures of depressive symptoms (Beck Depression Inventory II;
BDI-II) and global functioning (Outcome Rating Scale; ORS) as well
as monthly measures of depressive symptoms (Quick Inventory of
Depressive Symptomatology; QIDS-SR) and global symptom
severity (Brief Symptom Inventory; BSI).
2.3.1. Primary outcomes
2.3.1.1. Response, remission and recovery from depression.
Treatment responsewas defined as a 50% drop in BDI-II scores, from
the first baseline assessment to the last intervention assessment.
Remissionwas defined as a mean score of six or lower on the QIDS-
SR at the last intervention phase assessment, in line with estab-
lished cutoffs (Rush et al., 2003). Recovery was defined as the
absence of a DSM-IV depression diagnosis assessed with the SCID-I
at post-treatment.
2.3.2. Continuous primary outcome measures
2.3.2.1. Weekly assessment. The BDI-II was used as a weekly mea-
sure of depressive symptom severity (Beck et al., 1996). Each of the
21-items of the BDI-II consists of four statements with increasing
severity ranging from 0 to 3, resulting in a total score of 0e63 with
higher scores representing more depressive symptom severity. The
instructions of the original BDI-II were modified, asking partici-
pants to evaluate depressive symptoms during the past week
instead of the past twoweeks tomatch the timeframe of theweekly
assessment. The Dutch version of the BDI-II used in this study has
good psychometric properties (van der Does, 2002) and had
excellent internal reliability in the current study (a ¼ .91).
2.3.2.2. Monthly assessment. The QIDS-SR is a 16-item self-report
instrument measuring depressive symptom severity over the past
seven days (Rush et al., 2003). This shortened version of the original
30-item version (Rush, Gullion, Basco, Jarrett, & Trivedi, 1996)
correlates highly with clinical rating scales, such as the Hamilton
Rating Scale for Depression (Rush et al., 2003). Internal reliability of
the QIDS-SR in the current study was satisfactory (a ¼ .75).
2.3.3. Continuous secondary outcome measures
2.3.3.1. Weekly assessment. The ORS is a short, 4-item, self-report
instrument measuring individual, interpersonal, and social func-
tioning as well as overall wellbeing (Miller, Duncan, Brown, Sparks,
& Claud, 2003). In the current study the overall wellbeing scale was
used in all analyses. The ORS has adequate psychometric properties
(Miller et al., 2003).
2.3.3.2. Monthly assessment. The BSI is a 53-items self-report in-
strument measuring symptomatic distress along nine subscales
(Derogatis, 1992). In the current study, the global severity index
was used in all analyses. The original 5-point scale was modified to
a 100mmVisual Analogue Scale (VAS) because VAS scales might be
more sensitive to subtle changes (Breivik, Bjornsson, & Skovlund,2000). The BSI has good psychometric properties (de Beurs, 2004).
3. Procedure
Eligibility assessments, including SCID-I and SCID-II interviews,
were conducted by experienced clinicians at the clinic where
treatment was provided. Participants who met the inclusion
criteria were invited to an initial baseline assessment during which
study procedures were explained and informed consent was ob-
tained. Participants then completed the BDI-II and the ORS weekly
during the baseline phase, the exploration phase and the inter-
vention phase and the QIDS-SR and the BSI monthly. All ques-
tionnaires were completed via a secure web-based system:
Participants received an email once a week, on a fixed date, with
personal login information. At post-treatment SCID interviews
were conducted by the therapists or by an independent research
assistant.
3.1. Schema therapy for chronic depression
The ST intervention consisted of 8e10 sessions exploration and
up to 65 sessions active interventionwith a combined maximum of
75 sessions lasting 50 min each. The definite number of sessions
was dependent on individual progress in therapy. Therapy was
provided in weekly sessions initially and with lower frequency
sessions in later stages of treatment by four experienced therapists
(experience with ST varying between 5 and 12 years) according to
the methods described by Young (Young, Klosko, & Weishaar,
2003). During the exploration phase the therapist helped the pa-
tient to understand the schema concept, to establish relations be-
tween their predominant schemas, current problems and
developmental history, and to build a therapeutic alliance. In the
exploration phase schemas and current problems are explored but
no active attempts are made to change schemas or resolve current
problems. Although the exploration phase in the current study was
designed as an attentional control phase, it should be noted that the
work that is conducted during this phase is of high clinical
importance. For example, understanding the links between past
experiences and current problems as well as the formation of a
strong therapeutic relationship builds the basis for subsequent
therapeutic work conducted during the intervention phase. More-
over, the work conducted during the exploration phase might be
curative in itself, a possibility that is further described in the dis-
cussion. During the intervention phase underlying schemas are
targeted by the use of cognitive techniques, experiential tech-
niques, the therapeutic alliance (limited reparenting), and behav-
ioral techniques (as described in: Young et al., 2003). Towards the
end of the intervention phase a relapse prevention plan is estab-
lished and coping strategies to deal with situations that might
trigger relapses are established. A detailed description of the
treatment manual of ST for chronic depression that was followed in
this study is available elsewhere (Renner et al., 2013).
4. Data analysis
Statistical analyses of baseline and treatment effects were based
on the methods described in (Arntz, Sofi, & van Breukelen, 2013;
Malogiannis et al., 2014). Change in continuous primary and sec-
ondary outcome measures during the different treatment phases
was modelled using mixed regression analyses in SPSS version 22.
All available data was used for intent-to-treat principles.
First, we checked if symptoms remained stable in the absence of
treatment (baseline phase). Optimal model fit for different autor-
egressive covariance structures (AR1 and ARMA1,1) and different
representations of change over time (linear, quadratic, logarithmic)
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e73 69was determined by comparing the 2 Log Likelihood value of the
different models. The optimal model for the main continuous
outcome measure (BDI-II) had an ARMA1,1 covariance structure for
the repeated part with a logarithmic representation of time in the
fixed effects part of the model and included random intercepts and
slopes in the random part. Change over time was best represented
by log-transformed time, thus the fixed effect of log-transformed
time was used to test time development of depressive symptoms
and secondary continuous outcomes (BSI, ORS) during baseline.
Next, we tested treatment effects of the exploration and inter-
vention phase versus the baseline phase in terms of average scores
and linear change within phases. Fixed effects in the model were: a
general time effect (coded 0 when the first assessment took place),
dummy coded variables for the exploration and treatment phases
as a test of differences in average symptom levels within phases
relative to baseline, and linear time variables, individually centered
within each phase as a test of change in depressive symptoms
during the exploration and intervention phase. Again logarithmic
transformed time represented the general time effect best. The
model included random intercepts but no random slopes due to
convergence problems. When the general time effect was non-
significant the model was re-run without the general time effect.
Strength of treatment effects (Cohen's d) was calculated based
on model estimates by subtracting the last intervention value from
the last baseline value and by dividing the result by the SD based on
the variance of the random part of the model.5. Results
5.1. Description of the data
On average, each participant received 100 weekly assessments
during the course of the study (overall completion rate 77%).5.1.1. Adherence to exploration phase protocol
Therapists completed a session-report after each session,
recording the types of techniques that were used during the session
to assess treatment adherence. These exploration phase session
reports suggested good adherence to the exploration phase pro-
tocol: The most commonly used exploration phase strategies were
not aimed to change underlying symptoms or schemas and
included techniques for schema-mode identification (23%),
explaining the schema-therapy model and rationale (20%) and use
of techniques to build the therapeutic relationship (19%). On
average, 7% of the reported techniques used during the exploration
phase were intervention techniques, directed towards changing
schemas or resolving current problems, such as reparenting or
imagery rescripting. Note that the percentage of intervention
techniques used during the exploration phase reported here is
conservative and potentially an overestimation as the session
report checklist only had an option to indicate use of imagery-
rescripting (intervention technique) but no option to indicate use
of diagnostic-imagery (explorative technique). In some instances
therapists crossed out the word ‘rescripting’ but in other instances
it was unclear whether diagnostic-imagery or imagery-rescripting
was used and in these instances use of imagery during the explo-
ration phase was coded as use of an intervention technique.4 At the end of the funding period for this study 7 patients out of the 25 patients
who originally started with the study were still in treatment, receiving low-
frequency ST (about 1 session per month).5.2. Number of treatment sessions
On average, participants received 53 sessions ST (combined
exploration and intervention phase; SD ¼ 14.01; min ¼ 24
max ¼ 74). Patients who completed treatment on average had 55
sessions (SD ¼ 14.56) whereas patients who were still in treatment
at the end of the study period4 had on average 49 sessions
(SD ¼ 13.09).
5.3. Dropout
Of the 25 included patients 5 (20%) dropped out during the
baseline period. Three started a symptom focused treatment (two
CBT; one antidepressants), one stopped because of a new job and
lack of time and one stopped due to unspecified personal reasons.
5.4. Change in depression severity during baseline
There was a statistically significant logarithmic decrease in the
BDI-II total score during baseline, B ¼ 2.03, t(25.83) ¼ 2.56,
p ¼ .02, d ¼ 0.51, suggesting that depressive symptom severity
decreased during the baseline phase. As shown in Fig. 1, symptoms
decreased during the first weeks of baseline and then became
stable.
5.5. Primary outcomes
5.5.1. Response, remission and recovery
At the last intervention phase assessment, 8/20 (40%) patients
showed a positive response to treatment, 7/20 (35%) reached
remission and 12/18 (67%) recovered, i.e. did not meet a DSM-IV
diagnosis of depression (two patients could not be reached for
the post-treatment SCID).
5.5.2. Depressive symptom severity
Treatment effects on continues primary outcome measures
(BDI-II and QIDS-SR) are reported in Table 2 and Fig. 2. In the model
testing for treatment effects on depressive symptoms, assessed
weekly with the BDI-II, (i.e. the slope within the phases relative to
the slope of the general time effect), the time-intervention effect
was significant, B ¼ 0.07, t(68.95) ¼ 2.75, p ¼ .008, reflecting
that the intervention had a significant impact on change in
depressive symptoms that exceeded the overall decrease in
symptoms over time. The time-exploration phase effect was not
significant, B ¼ 0.14, t(385.99) ¼ 0.81, p ¼ .42, suggesting that
depressive symptoms did not change during the exploration phase.
The effect size for change in the BDI-II from baseline to post-
treatment was d ¼ 1.30.
Convergent effects were found for depressive symptoms
assessed monthly with the QIDS-SR (see Fig. 2 and Table 2). The
effect size for the QIDS-SR from baseline to post-treatment was
d ¼ 1.22.
5.6. Treatment effects on continuous secondary outcome measures
Treatment effects on continuous secondary outcome measures
(BSI and ORS) are reported in Table 3 and Fig. 2. After removing a
non-significant general time effect from the model testing change
in global symptom severity, there was a significant effect of time-
within intervention phase, B ¼ 0.54, t(32.53) ¼ 3.24, p ¼ .003,
indicating that the intervention phase was responsible for the
overall decrease in general symptom severity (Table 3; Fig. 2). The
effect size for the BSI from baseline to post-treatment was d ¼ 0.86.
In the model testing change in overall wellbeing, there was a

























Fig. 1. Graphical representation of decrease in depressive symptoms during baseline.
Table 2
Results of mixed regression analyses testing the effects of schema therapy on pri-
mary outcome measures.
Beta SE DF t p
BDI-II
Intercept 32.92 2.32 41.47 14.19 <0.001
Time1 2.31 0.63 567.46 3.67 <0.001
Exploration 2.31 1.20 505.93 1.93 0.06
Intervention 0.88 2.03 344.49 0.44 0.66
Time exploration 0.14 0.17 385.99 0.81 0.42
Time intervention 0.07 0.02 68.95 2.75 0.008
QIDS-SR including general time effect
Intercept 14.94 1.11 39.31 13.51 <0.001
Time1 1.22 0.71 293.91 1.72 0.09
Exploration 0.81 0.89 234.95 0.92 0.36
Intervention 1.29 1.61 244.13 0.80 0.43
Time exploration 0.81 0.97 290.52 0.84 0.40
Time intervention 0.18 0.08 47.40 2.30 0.03
QIDS-SR after deleting ns. general time effect
Intercept 14.27 1.03 31.69 13.79 <0.001
Exploration 0.35 0.58 234.32 0.60 0.55
Intervention 3.69 0.77 55.69 4.78 <0.001
Time exploration 0.26 0.91 308.50 0.28 0.78
Time intervention 0.25 0.06 44.28 4.04 <0.001
Note. 1Log transformed.
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e7370t(129.37) ¼ 4.20, p < .001 (Table 3; Fig. 2), indicating that the
intervention phase led to an increase in overall wellbeing. The ef-
fect size for improvements in overall wellbeing from baseline to
post-treatment was d ¼ 0.93.
6. Discussion
Many patients with chronic depression do not improve in cur-
rent pharmacological or psychological treatments for depression
highlighting the need of exploring new treatment options for this
patient group. The aim of this study was to test the effects of in-
dividual schema therapy (ST) in a case-series of 25 patients with
chronic depression.We found that 40% of the patients responded to
treatment, 35% remitted and 67% recovered, i.e. did not meet the
DSM-IV criteria for a depressive disorder at post-treatment. Rela-
tive to an overall decrease in symptoms over time, there was a
significant effect of the ST intervention on depressive symptoms.
After accounting for decreased symptom severity during the
baseline phase, by considering the last baseline phase assessments,the effect sizes for improvements in depressive symptoms during
the intervention phase were large.
Overall, these findings add to the emerging evidence that ST is a
promising treatment for patients with (chronic) depression (Carter
et al., 2013; Malogiannis et al., 2014). For example, Malogiannis
et al. (2014) conducted a case series for chronically depressed
women and found comparable remission (41.6%) and recovery
(60%) rates. The current study implemented a more stringent
control for change in symptoms over time as we implemented
multiple quasi-random baselines in our experimental designwhich
might explain the slightly higher remission rates in the study by
Malogiannis et al. (2014). In contrast to the current study,
Malogiannis et al. (2014) also found effects of the exploration phase
(labeled “phase b” or “introduction phase” in their study) on
depressive symptom severity. As described by the authors, their
exploration phase was not purely exploratory with a strong focus
on bonding between patient and therapists that took place in a
highly “nurturing environment” which might explain the effects
(Malogiannis et al., 2014). In contrast, the exploration phase in the
current study was primarily explorative. The absence of symptom
change during the exploration phase that was found in the current
study is in line with previous studies reporting that exploration of
symptoms in the context of developmental history (trauma) does
not improve symptoms (Arntz et al., 2013; Weertman & Arntz,
2007).
The findings of the current study also hint towards potential
mechanisms of change in ST for chronic depression. What accounts
for change in symptoms in psychotherapy (i.e. treatment mecha-
nisms) has been the topic of an ongoing debate in the literature,
with some researchers arguing that treatment-specific factors are
responsible for symptom improvements whereas others have
argued that so-called common factors, such as the therapeutic
alliance, are responsible for (early) change in symptoms (for a
recent discussion from both perspectives see e.g.: Hofmann &
Barlow, 2014; Laska, Gurman, & Wampold, 2014). The exploration
phase in the current study primarily included components that are
usually considered common factors, such as the formation of a
strong therapeutic relationship. The finding that the exploration
phase in the current study was not associated with symptom
improvement, while the intervention phase did lead to improve-
ment, suggests that common factors in isolation cannot account for
(early) symptom change in ST for chronic depression and that it is
the addition of specific factors in the intervention phase that
Fig. 2. Change in primary and secondary continuous outcome measures across treatment phases. The dashed line represents predicted change in each outcome measure if the
baseline would continue. Higher scores on the Outcome Rating Scale represents better functioning; Lower scores on all other measures represents less symptom severity.
Table 3
Results of mixed regression analyses testing the effects of schema therapy on sec-
ondary outcome measures.
Beta SE DF t P
BSI
Intercept 48.64 3.25 36.76 14.97 <0.001
Time1 2.96 1.94 313.67 1.52 0.13
Exploration 2.32 2.41 328.83 0.96 0.34
Intervention 2.07 4.39 277.91 0.47 0.64
Time exploration 1.00 2.56 326.30 0.39 0.70
Time intervention 0.36 0.21 86.02 1.73 0.09
BSI after deleting ns. general time effect
Intercept 47.11 3.07 29.97 15.36 <0.001
Exploration 0.47 1.58 233.61 0.30 0.77
Intervention 7.95 2.09 30.85 3.81 0.001
Time exploration 2.37 2.41 318.75 1.00 0.33
Time intervention 0.54 0.17 32.53 3.24 0.003
ORS
Intercept 36.00 3.91 130.40 9.20 <0.001
Time1 3.00 1.78 560.50 1.69 0.09
Exploration 2.03 3.27 509.18 0.62 0.53
Intervention 5.44 5.05 403.39 1.08 0.28
Time exploration 0.3 0.47 568.61 0.66 0.51
Time intervention 0.10 0.05 219.37 2.17 0.03
ORS after deleting ns. general time effect
Intercept 40.32 2.96 46.84 13.63 <0.001
Exploration 1.59 2.47 397.28 0.65 0.52
Intervention 13.10 2.21 177.91 5.91 <0.001
Time exploration 0.01 0.43 774.10 0.03 0.98
Time intervention 0.15 0.04 129.37 4.20 <0.001
Note. 1Log transformed.
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e73 71eventually leads to a better outcome. However, this could not be
tested directly here and the question of mechanisms of change in ST
(for chronic depression) remains an issue for future research.
Although results from case-series cannot directly be compared
to meta-analytic findings based on RCTs, the stringent control
phases in the current study allowed us to control for a general
decrease in symptoms over time (baseline phase) and for possible
effects of common factors, including receiving attention andempathy and the formation of a therapeutic relationship (explo-
ration phase). In this regard, the control phases in the current study
are comparable to waiting-list control conditions (baseline phase)
and non-active control treatment conditions (exploration phase) in
RCTs. However, note that the work conducted during the explora-
tion phase is still of high clinical importance as it forms the foun-
dation of the work conducted during the intervention phase. When
benchmarking the findings of the current study against the effect
size found in a meta-analysis of psychotherapy for chronic
depression (d ¼ 0.23; Cuijpers et al., 2010), ST in the current study
seems to perform well. We also tested for improvements in global
symptomatic distress and overall wellbeing as relevant secondary
outcomes. Participants improved with moderate to large effect
sizes on global symptomatic distress and overall wellbeing, indi-
cating that the positive effects of ST on depressive symptoms
extended to broader aspects of distress and functioning.
Although five patients dropped out during the baseline phase
none of the participants dropped out from treatment. Studies of ST
for personality disorder have reported relatively lower dropout
rates in ST compared to treatment as usual (Bamelis et al., 2013) or
psychotherapy control conditions (Giesen-Bloo et al., 2006). ST
places special emphasis on building a strong therapeutic relation-
ship during the exploration phase (Young et al., 2003) which could
protect from dropout. In line with this, it has been shown that
negative therapeutic alliance ratings predict dropout, and that the
high treatment retention of ST probably relates to early strong
therapeutic alliance (Spinhoven, Giesen-Bloo, van Dyck, Kooiman,
& Arntz, 2007). In this sense, the exploration phase in the current
study might have had a therapeutic value by protecting from
dropout. Note that with the current design this possibility cannot
be tested.
The current study included a quasi-random baseline period to
control for change in symptoms over time in the absence of active
treatment. Unexpectedly, depressive symptoms decreased initially
and then became stable during the course of the baseline. At least
two explanations might account for this finding. The initial
decrease in symptoms during baseline represents 1) a ‘true’
F. Renner et al. / J. Behav. Ther. & Exp. Psychiat. 51 (2016) 66e7372spontaneous improvement in depressive symptoms or 2) a mea-
surement artifact. In favor of the first explanation, participants
might have experienced a strong motivation to start with a novel,
promising treatment in an academic context. This might have led to
an initial alleviation in depressive symptoms during the first weeks
of the study (i.e. an expectancy effect). In favor of the second
explanation, participants might have overestimated their symptom
severity and due to the repeated completion of and reflection on
the questionnaires established a new, ‘true’, stable baseline. In line
with this, it has been shown that a change in BDI scores in the
absence of treatment is a function of the frequency of test admin-
istration with weekly administration resulting in decreases
whereas BDI scores remain stable during bi-weekly or monthly
administration (Longwell & Truax, 2005). Moreover, patients with
depression become more accurate in assessing self-reported
depressive symptoms over time (Fokkema, Smits, Kelderman, &
Cuijpers, 2013). Given that patients in the current study, by defi-
nition, suffered from depression for at least two years, it is unlikely
that they experienced a ‘true’ decrease in symptoms during base-
line. Note that based on the current study it is not possible to
empirically support either explanation. One implication of this
finding is that depressed patients participating in treatment
outcome studies should be re-assessed until symptom severity is
stable instead of relying on one pre-treatment or baseline
assessment.
A number of important limitations of this study should be
mentioned when interpreting the results. First, this study was a
case series which by design does not include a control group.
However, by including a non-treatment multiple baseline phase
and an exploration phase, symptom improvement over time could
be attributed to the intervention. Second, the decrease in depres-
sive symptoms during the baseline phase complicated the detec-
tion and estimation of treatment effect sizes. Due to the unstable
baseline we had to (implicitly) rely on extrapolation of change
assessed during the baseline to the exploration and intervention
periods. Third, due to the small sample size we were not able to
explore predictors of treatment effects in this study, an important
issue for future studies. Finally, post-treatment SCID assessments
were conducted by study therapists, who were not blind to the
treatment and might therefore have been biased in their judgment
which could account for the relatively high recovery rates
compared to response and remission rates in this study.
In conclusion, this study adds to the accumulating evidence that
ST might be an effective treatment for patients with chronic
depression. The low dropout rates in previous ST studies and the
absence of dropout from the intervention phase in the current
study highlight the acceptability of ST by patients. Although there is
now emerging evidence that ST might be an effective treatment for
(chronic) depression, future RCT based studies in larger samples are
needed to determine the efficacy of ST for chronic depression and
the comparative efficacy of ST relative to other interventions before
the findings can be disseminated in clinical practice.
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